Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: Retrospective analysis

Table 1 Statistical data of the groups with and without preoperative transarterial chemoembolization

Demographics	TACE (n = 88)	No TACE (n = 116)	t	P value
Age (yr)	49.34 ± 8.06	50.90 ± 7.70	-1.401	0.163
Child	7.33 ± 2.69	7.23 ± 2.46	0.267	0.789
MELD	8.36 ± 7.16	8.07 ± 5.74	0.324	0.747
IBL (mL)	2944.32 ± 4008.34	2528.79 ± 2681.56	0.886	0.377
IOA (mL)	1910.34 ± 2902.87	1539.53 ± 2532.91	0.972	0.332
AFP (ng/L)	3439.08 ± 6623.56	1922.59 ± 5180.01	1.835	0.068
Disease-free survival time (mo)	20.77 ± 17.52	32.79 ± 22.63	-4.131	< 0.001a
Survival time with tumor (mo)	1.88 ± 3.10	0.68 ± 2.10	3.278	0.001a

^aP < 0.05, TACE vs no TACE. TACE: Transarterial chemoembolization; Child: Child-Turcotte-Pugh classification; MELD: Model for end-stage liver disease; AFP: α-fetoprotein; IBL: Intraoperative blood loss; IOA: Intraoperative autotransfusion.